Cardiovascular risk assessment for osteoporosis patients considering Romosozumab.

Macrae, F; Clark, E M; Walsh, K; Bailey, S-J; Roy, M; Hardcastle, S; Cockill, C; Tobias, J H et al. · Bone · 2025

review · Level V

Where this comes from

Abstract

Cardiovascular risk scoaring tools are suitable for but not interchangable within the osteoporosis clinic.

Medical subject headings